# Phase 2 Study of Fingolimod in Lung Cancers

> **NCT06424067** · PHASE2 · RECRUITING · sponsor: **Medical University of South Carolina** · enrollment: 38 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Small-cell Lung Cancer

## Interventions

- **DRUG:** Fingolimod 0.5 milligram (mg) [Gilenya]

## Key facts

- **NCT ID:** NCT06424067
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06424067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06424067, "Phase 2 Study of Fingolimod in Lung Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06424067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*